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ABSTRACT 
Purpose: Cancer survivors are increasingly expected to manage the consequences of cancer and its treatment 
for themselves. There is evidence that self-efficacy is important for successful self-management and that this 
can be enhanced with support. The purpose of this study was to assess self-efficacy to manage problems in the 
year following primary treatment. 
Methods: This cross-sectional online survey included cancer survivors who had completed their treatment 
within the past 12 months. Self-efficacy was assessed and variables expected to be associated with self-efficacy 
were measured using validated scales including quality of life, well-being, illness perceptions, depression, social 
support and self-management strategies. 
Results: 182 respondents (mean age 50; 81% female) completed the survey.  They had been treated for a range 
of cancers; most commonly breast (45%).  Self-efficacy scores varied between individuals and according to the 
illness related task to be managed. Respondents were least confident in managing fatigue and most confident in 
accessing information about their cancer. Individuals most likely to report low self-efficacy were: women, those 
experiencing higher levels of pain and/or depression, lower well-being scores, lower socio-economic status, low 
levels of social support or a more negative perception of cancer.  
Conclusions: Self-efficacy to self-manage problems faced as a consequence of cancer and its treatment can vary 
widely in the year following treatment. Fatigue may be particularly difficult to manage. Variations in self-
HIILFDF\KLJKOLJKWWKHLPSRUWDQFHRIDVVHVVLQJVSHFLILFSUREOHPVIDFHGDQGSHRSOH¶VFRQILGHQFHWRPanage them 
in order to tailor appropriate self-management support. 
Keywords: Self-management; cancer survivors; self-efficacy; confidence; neoplasms 
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INTRODUCTION 
By 2050, an estimated 70 million people will be living with a diagnosis of cancer worldwide; an almost three-
fold increase since 2002 [1]. Rising survival rates are due to improvements in detection and treatments, with 
many people faring well. However, cancer and its treatment can have a considerable and long-term impact on 
everyday life [2, 3, 4]. With an ageing population and an aftercare system WKDWLVQRWPHHWLQJSHRSOH¶VQHHGV, 
there is growing concern about how best to support cancer survivors and new models of aftercare are being 
developed and evaluated [5, 6, 7]. 
Self-management in cancer survivorship has been defined as ³DZDUHQHVVDQGDFWLYHSDUWLFLSDWLRQE\WKHSHUVRQ
in their recovery, recuperation and rehabilitation, to minimise the consequences of treatment, and promote 
survival, health and well-EHLQJ´>6]. This will involve managing consequences of cancer and its treatment 
(physical, psychological, social, practical problems), understanding how and when to seek support, recognising 
and reporting signs and symptoms of possible disease progression, and making lifestyle changes to promote 
health, well-being and survival. People will be supported to self-manage in a variety of ways but the onus will 
be on them to initiate contact with healthcare professionals and others to support them [6]. We do not yet 
understand how able people feel to self-manage. Failure to provide appropriate support could have serious 
consequences with individuals becoming overburdened, leading to less self-management, greater inequalities, 
reduced access to services and poorer health and well-being [8]. 
Self-management can empower cancer patients, increase their confidence to manage problems associated with 
the disease and its treatment and enhance quality of life [9, 10]. Foster and Fenlon [11] have set out a framework 
for recovery of health and well-being in cancer survivorship which has self-management and support for self-
management as essential components. One element of the framework is cancer related self-efficacy; belief that 
one can successfully execute behaviour required to produce expected outcome [12] in relation to 
consequences of cancer and its treatment. An adapted version of the framework is illustrated in Figure 1 
to reflect elements assessed in this study and demonstrating that the focus of the study is on the factors 
predicted to be associated with cancer related self-efficacy.  Higher self-efficacy has been associated with a 
greater effort and persistence to cope with obstacles [13] and enhanced well-being [14].  In people affected by 
cancer, a high degree of self-efficacy is associated with increased self-care behaviours and decreased physical 
and psychological symptoms [15].  Self-efficacy is likely to change according to the task to be self-managed and 
is subject to change [16, 17]. It has therefore become the target of many self-management interventions [10]. 
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Self-efficacy is not a general trait and therefore a person cannot be described as having high self-efficacy 
or low self-efficacy in all situations. Rather, individuals have beliefs about their ability to carry out tasks 
and these will vary according to the context and the nature of the task. For example, someone may have 
high self-efficacy in the workplace but low self-efficacy in relation to exercise. Going further, someone 
who reports high self-efficacy in the work place may have quite different self-efficacy beliefs when work 
related self-efficacy is examined in more detail e.g. high self-efficacy for managing a team but low self-
efficacy for delivering a pitch to an audience. For this reason we have explored cancer related self-efficacy 
generally and then looked at different aspects of this to understand areas where cancer survivors may 
have lower self-efficacy to inform targeted intervention. 
Figure 1: Recovery of health and well-being in cancer survivorship [11] 
 
 
Little is known about FDQFHUVXUYLYRUV¶cancer-related self-efficacy and how problems are managed in the year 
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1. Cancer related self-efficacy will be influenced by socio-demographic and clinical variables 
2. Cancer related self-efficacy will be positively associated with well-being 
3. Cancer related self-efficacy will be negatively associated with depression 
4. Cancer related self-efficacy will be negatively associated with a more threatening perception of 
illness 
5. Cancer related self-efficacy will be positively associated with social support 
The purpose of the study was to identify who is most likely to need support to self-manage cancer related 
problems in the year following primary treatment as indicated by lower self-efficacy.  
METHODS 
Design 
This was a cross-sectional, online survey of adults who had completed primary cancer treatment in the past year.  
Participants 
Eligible participants were:  \HDUV; able to complete the survey online in English; had completed primary 
cancer treatment in the past 12 months; and were resident in the UK. A sample size calculation was performed 
based on expected variations in the Self Efficacy for Managing Chronic Disease Scale [18]. Previous studies 
using this measure have indicated wide variations in self-efficacy scores [19, 20], therefore, the calculation 
allowed for a 40% difference between scores; assumed a statistical significance level of 0.05; and a test with 85% 
power, giving a required sample size of 170. 
Procedure 
Ethical approval was granted by the University (REF: FoHS-ETHICS-2011-051). The survey was created and 
managed using iSurvey [21].  Recruitment took place August - December 2011. The survey was advertised and 
linked to 35 charity websites (including social media links), University website, staff bulletins, and posters in 
260 libraries. Twitter and Facebook accounts were created. Adverts directed individuals to the study website. 
Before completing the survey participants confirmed they had read the Patient Information Sheet and met the 
inclusion criteria.     
Measures 
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Validated measures, previously used in cancer populations and informed by our recovery framework were 
included [11]. Participants provided socio-demographic data and reported health service.  
Primary outcome: Self-Efficacy for Managing Chronic Disease Scale was used [18] to measure self-efficacy in 
people with chronic conditions and has been used with cancer patients [22]. Respondents rate their confidence to 
perform 6 self-management behaviours (1=µNot at all CRQILGHQW¶WR10=µTotally CRQILGHQW¶.  A mean score is 
calculated (range 1 to 10). A high score indicates high self-efficacy.  We added 5 cancer specific self-
management behaviours using the same rating scale and calculated a mean score (range 1-10). The new Cancer 
Survivors Self-efficacy Scale of 11 items was tested using non-parametric, item-response theory (Mokken Scale 
analysis) [23]. The full set of 11 items formed a strongly homogenous, uni-dimensional scale of self-efficacy 
(H=0.54) with excellent reliability (Alpha=0.92). We report the mean scale score and also look at individual 
items to understand the range of self-efficacy beliefs for different aspects of cancer related self-efficacy. 
Health and well-being: The Quality of Life in Adult Cancer Survivors scale (QLACS) has been validated with 
long-term cancer survivors [24].  The scale consists of 12 domains (Generic and Cancer Specific). Respondents 
indicate the frequency with which they experienced each quality of life issue in the last two weeks  µ1HYHU¶WR
 µ$OZD\V¶Each domain is scored (range 4-28). Higher scores represent poorer quality of life.   
The Personal Wellbeing Index (PWI-A) measures subjective quality of life among adults. Respondents indicate 
their global satisfaction with life and satisfaction with 8 different aspects of their life (0=µCompletely 
Dissatisfied¶ to 10=µCompletely Satisfied¶) [25].  A mean score is calculated and converted into a percentage. A 
higher value indicates greater sense of well-being. The PWI has been used to assess quality of life in people 
with spinal cord injury [26], older people [27] and random samples, with good validity and reliability [28].  
Personal factors: The Brief Illness Perception Questionnaire (Brief IPQ) is an 8 item scale assessing cognitive 
and emotional representations of illness [29].  Each item is scored on a scale of 0 to 10 (E.g.  µ1RDIIHFWDWDOO¶
WR µ6HYHUHO\DIIHFWVP\OLIH¶. A total score (after appropriate reverse scoring; range 0 to 80) represents the 
degree to which the illness is perceived as threatening or benign (Broadbent, personal communication). Higher 
scores reflect a more threatening view of illness. The instrument has been used with people with cancer [30].   
The Center for Epidemiologic Studies Depression Scale (CES-D) assesses how often (0=µRarely or None of the 
Time¶ to 3=µAll of the Time¶) participants experienced a range of symptoms in the past week and yields a total 
score (after appropriate reverse scoring; range 0 to 60) [31].  A higher score indicates more frequent depressive 
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symptoms. A score 16 suggests psychological distress. A higher clinical cut-off of 20 or 27 has been 
suggested for cancer patients; although specificity may be reduced i.e. the number of people who are incorrectly 
identified as NOT having minor or major depression is higher [32].  The CES-D has been established as reliable 
and valid for measuring depressive symptoms in people with cancer [33].  
Environmental factors: The Medical Outcomes Study (MOS) social support survey measures availability of 
social support [34].  Respondents indicate how often different kinds of support are available to them  ¶1RQH
RIWKH7LPH¶WR ¶$OORIWKH7LPH¶. There are 18 items in 4 subscales. A mean score is calculated to produce 
an overall support index: a higher score denotes a greater level of social support.  To compare to published 
means, scale scores were transformed to a 0-100 scale. This survey has been tested for validity and reliability 
with cancer survivors [35].  
 
Analyses  
The level of missing data was extremely low. In cases where data contributing to a validated measure 
were missing the instructions given by the authors of the measure for the treatment of missing data were 
followed. Where no explicit instructions for missing data were given, measures based on the sum of scores 
were not calculated if any items were missing and measures based on a mean score were not calculated if 
there were more than 2 items missing. Independent t-tests, one-way analyses of variance, Pearson and 
Spearman rank correlations were performed to establish relationships between self-efficacy and other variables.  
A backward elimination method was used to perform linear regression analysis. Separate regressions, with 
variables grouped according to the conceptual framework and significant variables, were carried forward to a 
final analysis. Collinearity diagnostics for all regression models were run; a threshold of < 0.1 for tolerance and > 
10 for the variance inflation factor was observed [36, 37].  
RESULTS 
234 people completed the online survey. 182 met the eligibility criteria and were included in the analyses; 52 
were ineligible (50 had not completed treatment in past 12 months; 2 entered no data). 
Characteristics of the sample 
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Socio-demographic and clinical data are presented in Table 1. Mean time since treatment completion was 5.36 
months. Most respondents were female and described themselves as White British.  Ages ranged from 23 to 79 
years.  Respondents reported 21 different cancer diagnoses.  The largest single group were breast cancer 
survivors. 177 (97%) respondents had received surgery, radiotherapy or chemotherapy (or a combination).  The 
most common treatment was surgery.  Comorbidities, such as asthma, diabetes and arthritis, were reported by 
almost 40% of respondents.   
Health service use 
All respondents had used health services at least once in the past year: 174 (96%) had seen a General 
Practitioner, 159 (87%) an oncologist, 153 (84%) a cancer nurse and 149 (82%) a surgeon.  131 (72%) had 
stayed overnight in hospital.  
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Table 1: Socio-demographic and clinical characteristics of respondents 
Characteristic Number or mean (%) 
n=182 
Age  50 years  (SD 9.505) 
Gender  Female:  147 (80.8) 
Male:       35 (19.2) 
Ethnicity  
White British 
White Irish 
Other White background 
White and Hispanic 
Other mixed background 
 
166 (91.2) 
5 (2.7) 
9 (4.9) 
1 (0.5) 
1 (0.5) 
Highest educational attainment 
Higher degree 
Degree 
A levels or equivalent 
GCSE/O levels or equivalent 
No formal qualifications 
 
33 (18.1) 
56 (30.8) 
46 (19.8) 
32 (23.1) 
15 (8.2) 
Domestic status 
Married 
Divorced/separated 
Living with partner 
Single 
Widowed 
Missing 
 
103 (56.6) 
27 (14.8) 
22 (12.1) 
25 (13.7) 
3 (1.6) 
2 
Employment status 
Employed 
Not employed 
 
132 (72.5) 
50 (27.5) 
Months since completion of treatment  5.36 (SD 3.848)  
Treatment received in past 12 months 
Surgery  
Radiotherapy 
Chemotherapy 
 
119 (65.4) 
102 (56.0) 
99 (54.4) 
Cancer type 
Breast 
Urological 
Gynaecological 
Gastro-intestinal 
Haematological 
Other 
Missing 
 
82 (45.1) 
23 (12.6) 
21 (11.5) 
18 (10.0) 
17 (9.3) 
13 (7.1) 
8 
Comorbidities reported  70 (38.5)  
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Self-efficacy to manage consequences of cancer and its treatment  
The mean score on the Cancer Survivors Self-Efficacy scale was 6.87 (SD 1.79)1 (range: 1-10; higher score = 
greater self-efficacy). The mean score for each individual item was calculated to highlight variations in self-
efficacy across tasks.  Self-efficacy to manage fatigue was lowest and self-efficacy to access information about 
cancer and treatment effects was highest as shown in Figure 2. 
Figure 2: Self-efficacy to manage consequences of cancer and its treatment. Measured by the Cancer Survivors 
Self-Efficacy Scale (high score denotes higher self-efficacy) 
 
Hypothesis 1: Cancer related self-efficacy will be influenced by the socio-demographic and clinical 
variables 
Some socio-demographic variables were associated with self-efficacy: male respondents reported higher self-
efficacy than females (t=2.595, p < 0.05);  those who believed their cancer affected the amount or kind of work 
that they could do were more likely to have lower self-efficacy than those who did not (t=5.857, p<0.01); home 
owners or those renting from a private landlord reported higher self-efficacy than those renting from a Council 
or Housing Association or living in temporary or other accommodation (t= -2.608, p<0.05). Contrary to 
                                                          
1
 Mean score for  the six items of the original Self-Efficacy for Managing Chronic Disease 6-item Scale was 
6.34 (SD 2.05)   
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Hypothesis 1, cancer-related self-efficacy did not differ significantly by age, marital, or employment status; or 
clinical characteristics: type of cancer or treatment, time since diagnosis, or comorbidities.   
Health and well-being 
Hypothesis 2: Cancer related self-efficacy will be positively associated with well-being 
The Generic Summary Score for QLACS was 109.20 (SD 22.68) and the Cancer Specific Summary was 
57.20 (SD 19.57). QLACS domain scores ranged from 10.97 (Distress-Family), the least frequently experienced 
problem, to 18.28 (Energy/Fatigue), the most frequently experienced problem.  67% of respondents reported 
that they frequently, very often or always experienced problems with fatigue (score 5). In terms of concerns 
about recurrence VFRUHVIUHTXHQWO\YHU\RIWHQRUDOZD\V, 50% of respondents reported worrying about 
dying from cancer, 67% reported worry about recurrence, 53% reported worrying that pains were a sign of 
recurrence, 47% reported being preoccupied with concerns about cancer.  Mean PWI was 58.7 (SD 21.8) where 
a lower score indicates poorer well-being.  The normative range for Western populations is 70-80 [36]. There 
were strong correlations between self-efficacy and QLACS (GSS r=-0.65, p<0.001; CSS r=-0.52, p<0.001) and 
PWI (r=0.746, p<0.001).  Better health and well-being was associated with higher self-efficacy across all 
domains (p<0.001) confirming Hypothesis 2.   
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Table 2: Quality of life, illness perceptions, depressive symptoms, and perceived social support  
Measure n Mean (SD) 
 
Quality of Life in Adult Cancer Survivors  
(scores: 4-28; high score = more problems) 
  
Energy/Fatigue 179 18.28 (4.94) 
Distress-Recurrence 182 18.19 (6.53) 
Positive feelings 181 16.94 (5.13) 
Benefits 182 16.63 (6.12) 
Sexual Problems 175 16.26 (6.64) 
Pain 181 15.05 (5.79) 
Negative feelings 179 15.02 (5.14) 
Cognitive Problems 179 14.59 (5.68) 
Appearance 180 14.28 (6.93) 
Financial Problems 178 13.67 (7.46) 
Social Avoidance 175 13.53 (6.44) 
Distress-Family 182 10.97 (5.45) 
QLACS Generic Summary Score (GSS range 59-161) 168 109.20 (22.68) 
QLACS Cancer Specific Summary (CSS range 18-101) 176 57.20 (19.57) 
   
Personal Wellbeing Index  
(scores: 0-100; high score = better wellbeing) 
181 58.7 (21.8) 
 
  
Brief Illness Perception Questionnaire  
(scores: 0-80; high score = more threatening perception) 
179 39.93 (13.70) 
 
  
MOS social support survey (scores: 0-100; high score = more support)   
Overall support index 174 67.06 (27.6) 
Emotional/informational support 179 61.10 (31.19) 
Tangible support 178 66.92 (33.49) 
Affectionate support 177 75.99 (32.06) 
Positive social interaction 179 73.09 (29.51) 
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Personal factors 
Hypothesis 3: Cancer related self-efficacy will be negatively associated with depression 
Hypothesis 4: Cancer related self-efficacy will be negatively associated with a more threatening 
perception of illness 
Mean CES-D was 21.04 (SD 12.44; range 0-60). 62% had scores of 16, suggesting clinically significant 
psychological distress; 49% KDGVFRUHVand 32% scores . It is unclear what an appropriate cut-off 
should be therefore we examined individual items. UHSRUWHGWKDWWKH\µIHOWGHSUHVVHG¶µDOORIWKHWLPH¶, 20% 
WKDWWKH\µIHOWGHSUHVVHG¶µRFFDVLRQDOO\/moderate amount of the time¶. UHSRUWHGWKDWWKH\µUDUHO\¶IHOW
hopeful for the future. 66% of respondents reported restless sleep (µDOORIWKHWLPH¶- 40%; or 
µRFFDVLRQDOO\PRGHUDWHDPRXQWRIWKHWLPH¶- 26%) which may explain the high total CES-D scores. Higher 
CES-D scores were associated with lower levels of self-efficacy (r=-0.75, p<0.001) confirming Hypothesis 3. 
Mean Brief IPQ was 39.93 (SD 13.70; range 0-80) where a higher score indicates more threatening perception 
of the illness. A more threatening perception of illness was associated with poorer self-efficacy (r=-0.41, 
p<0.001) confirming Hypothesis 4. 
 
Environmental factors 
Hypothesis 5: Cancer related self-efficacy will be positively associated with social support 
The mean overall support score was 67.07 (SD 27.6). Least support was reported for 
emotional/informational support and most support for positive social interaction. However, there is wide 
variation in the scores for overall social support and the sub-scale scores. Most participants reported 
adequate social support (score  4; most to all of the time) in terms of positive social interaction (65.3%), 
affectionate (69%) and tangible (53.2%) support. Only 40% reported adequate emotional/informational support 
(e.g. someone to confide in, someone to give good advice and information). Higher levels of social support were 
associated with higher self-efficacy (r=0.53, p<0.001) confirming Hypothesis 5.   
Regression Analysis 
We conducted a backward, stepwise regression analysis to investigate relationships between self-efficacy and 
the variables proposed in the selected elements of our conceptual framework as illustrated in Figure 1 [11].  
The final model for self-efficacy (Table 3) included: QLACS pain subscale, PWI, CES-D, accommodation 
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(owner occupier/renting privately versus not), gender, illness perception and social support. The model accounts 
for 76% of the variance in self-efficacy.  Variables most strongly associated with a low self-efficacy score were: 
higher level of pain; lower subjective sense of well-being; higher depression; not living in owner-occupied or 
privately rented accommodation; being female; having a more threatening perception of cancer; having a lower 
level of social support. 
Table 3: Regression analysis of factors associated with self-efficacy (n=182) 
Model Unstandardised 
Coefficients 
 Standardised 
Coefficients 
95% Confidence interval for 
B 
B Standard error Beta   
Constant 7.561 0.614  6.348 8.773 
Pain (QLACS) -0.052 0.015 -0.167** -0.082 -0.022 
Personal 
wellbeing 
(PWI) 
0.199 0.052 0.240** 0.096 0.301 
Depression 
(CES-D) 
-0.029 0.009 -0.200** -0.047 -0.011 
Housing 0.414 0.206 0.081* 0.007 0.821 
Gender -0.415 0.188 -0.090* -0.785 -0.044 
Illness 
perception 
(IPQ) 
-0.038 0.008 -0.284** -0.053 -0.022 
Social support 
(MOS) 
0.282 0.081 0.171** 0.123 0.442 
R2= 0.758, * p<0.05, ** p <0.01 
DISCUSSION 
Compared to studies of cancer survivors participants in this online survey were doing less well on almost all 
quality of life dimensions [24]. However participants in this study had completed their primary treatment more 
UHFHQWO\LQWKHSDVWPRQWKVYV\HDUVDJRThey also reported higher rates of depression, as measured by 
the CES-D, than reported elsewhere, for example, in head and neck cancer patients up to 6 weeks post 
radiotherapy [32] and breast cancer survivors 1-5 years post diagnosis [38]. The numbers remained high for 
clinically significant depression when we raised the clinical cut-off as suggested in the literature for individuals 
with cancer [32]. Respondents reported greater frequency of fatigue (67% reporting frequently to always) than 
previously reported amongst cancer survivors [5]. The high scores may in part be explained by high fatigue 
OHYHOVDQGSUREOHPVZLWKVOHHSUHSRUWHGE\WKHSDUWLFLSDQWVUDWKHUWKDQWKHLUSHUFHSWLRQVRIµIHHOLQJGHSUHVVHG¶
so this needs to be interpreted with caution. In relation to personal well-being participants were doing less well 
than the general population [28]. Participants in this study had comparable social support scores to others with 
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chronic conditions [34]. There was wide variation in self-reported social support in this sample across the 
four domains of social support. 
Confidence to self-manage problems faced as a consequence of cancer and its treatment varied widely in the 12 
months following treatment.  Our results are comparable with a study of patients with chronic conditions 
attending general practices in Germany [39]. Given the higher than expected level of unmet need in our group ± 
particularly in relation to fatigue ± it is important to highlight that participants reported low self-efficacy to 
manage the consequences of fatigue in their everyday lives. Lowest self-efficacy scores were for managing 
fatigue, emotional distress and health problems.  
Relatively high self-efficacy scores for accessing information and support, suggests a sample comfortable with 
accessing information and engaging with support services.  This may reflect the relatively high levels of 
education the sample reported, compared to the general population, as well as a relatively high level of computer 
literacy implied by participating in the online survey.  We have established a clinical cohort of colorectal cancer 
patients and plan to explore these issues with the cohort participants [40].  
As indicated above levels of self-efficacy varied according to the task, supporting the view that self-efficacy is 
domain specific [16, 17]. This underlines the importance of considering YDULDWLRQLQDQLQGLYLGXDO¶VVHOI-efficacy 
for self-managing different problems associated with cancer and its treatment, rather than viewing 
individuals as having confidence or not in a general sense.  Domain specific cancer related self-efficacy 
measures are likely to be valuable in helping to identify cancer survivors who lack self-efficacy for particular 
tasks or behaviours.  Identification of low self-efficacy in specific behaviours could facilitate targeted support 
for cancer survivors to better self-manage consequences of cancer and treatment.   
Those most at risk of overall low self-efficacy to manage the consequences of their cancer and its treatment 
were women, those experiencing higher levels of pain, depression, lower wellbeing scores, who did not own 
their own home or live in privately rented accommodation, had low levels of social support and a more 
threatening perception of their cancer. Our conceptual model of recovery [11] predicts which factors will impact 
DQLQGLYLGXDO¶V cancer-related self-efficacy.  In the model, subjective health and well-being, environmental 
factors and personal factors influence cancer-related self-HIILFDF\ZKLFKLQWXUQKDVDQHIIHFWRQDQLQGLYLGXDO¶V
choice of self-management strategies.  These study findings lend support to this model, although as these data 
are from a cross-sectional survey we cannot determine causality.  Our results, therefore, highlight the possibility 
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of targeting support to cancer survivors who are likely to have lower self-efficacy to manage cancer related 
consequences so that they can be supported to self-manage.  
Some limitations of this study should be considered when interpreting the ILQGLQJV$QDO\VLVRIUHVSRQGHQWV¶
socio-demographic characteristics suggests that these cancer survivors were not representative of the wider 
population of people living with and beyond cancer.  Those taking part in this study were self-selected, younger 
and more likely to be female, White British and achieved a higher level of education than might be expected in a 
representative sample of cancer survivors [41, 42]. In addition, the cancer survivors who responded to this 
survey reported higher levels of psychological distress than might have been expected.  In a cancer population, 
about 20% would be expected to have clinically significant levels of distress [33]. We have established a 
prospective clinical cohort of colorectal cancer survivors and will explore cancer related self-efficacy further in 
this group [40].  
Conclusions 
This study demonstrates that cancer survivors have varying levels of self-efficacy according to different tasks to 
be managed in the year following treatment. This has implications for how self-efficacy is assessed to identify 
specific areas of low confidence among patients living with cancer or treatment related problems.  The 
regression model indicates a number of factors which may help identify patients at risk of having low 
confidence to manage problems associated with cancer.   
Given that growing numbers of cancer survivors will be expected to self-manage their aftercare it is important to 
assess confidence to self-manage the different elements of aftercare, for example, managing consequences of 
cancer and its treatment; accessing information and support as required; identifying signs and symptoms of 
possible disease progression; and making lifestyle changes as appropriate. This has implications for targeting 
support designed to improve self-efficacy. 
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